These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28604162)

  • 21. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
    Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
    Lemmermann NA; Reddehase MJ
    Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immune response to CMV infection and vaccination in mice, monkeys and humans: recent developments.
    Hill AB
    Curr Opin Virol; 2018 Feb; 28():161-166. PubMed ID: 29459261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal Kinetics of Cytomegalovirus-Specific T-Cell Immunity and Viral Replication in Infants With Congenital Cytomegalovirus Infection.
    Chen SF; Holmes TH; Slifer T; Ramachandran V; Mackey S; Hebson C; Arvin AM; Lewis DB; Dekker CL
    J Pediatric Infect Dis Soc; 2016 Mar; 5(1):14-20. PubMed ID: 26908487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus-specific CD4 and CD8 T cell responses in infants and children.
    Lidehäll AK; Engman ML; Sund F; Malm G; Lewensohn-Fuchs I; Ewald U; Tötterman TH; Karltorp E; Korsgren O; Eriksson BM
    Scand J Immunol; 2013 Feb; 77(2):135-43. PubMed ID: 23216075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
    Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG
    Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time.
    Iancu EM; Corthesy P; Baumgaertner P; Devevre E; Voelter V; Romero P; Speiser DE; Rufer N
    J Immunol; 2009 Jul; 183(1):319-31. PubMed ID: 19542443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution.
    Smith C; Brennan RM; Tey SK; Smyth MJ; Burrows SR; Miles JJ; Hill GR; Khanna R
    J Virol; 2016 Aug; 90(16):7497-507. PubMed ID: 27279616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
    Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How does cytomegalovirus factor into diseases of aging and vaccine responses, and by what mechanisms?
    Aiello AE; Chiu YL; Frasca D
    Geroscience; 2017 Jun; 39(3):261-271. PubMed ID: 28624868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple epitopes in the murine cytomegalovirus early gene product M84 are efficiently presented in infected primary macrophages and contribute to strong CD8+-T-lymphocyte responses and protection following DNA immunization.
    Ye M; Morello CS; Spector DH
    J Virol; 2004 Oct; 78(20):11233-45. PubMed ID: 15452242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoptive transfer of cytomegalovirus-specific effector CD4+ T cells provides antiviral protection from murine CMV infection.
    Jeitziner SM; Walton SM; Torti N; Oxenius A
    Eur J Immunol; 2013 Nov; 43(11):2886-95. PubMed ID: 23921569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional Exhaustion Limits CD4+ and CD8+ T-Cell Responses to Congenital Cytomegalovirus Infection.
    Huygens A; Lecomte S; Tackoen M; Olislagers V; Delmarcelle Y; Burny W; Van Rysselberge M; Liesnard C; Larsen M; Appay V; Donner C; Marchant A
    J Infect Dis; 2015 Aug; 212(3):484-94. PubMed ID: 25657256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity.
    Giulieri S; Manuel O
    Expert Rev Mol Diagn; 2011 Jan; 11(1):17-25. PubMed ID: 21171917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virology. A vaccine monkey wrench?
    Hengel H; Koszinowski UH
    Science; 2010 Apr; 328(5974):51-2. PubMed ID: 20360096
    [No Abstract]   [Full Text] [Related]  

  • 36. CD8(+) T-cell immunity to cytomegalovirus.
    Moss P; Khan N
    Hum Immunol; 2004 May; 65(5):456-64. PubMed ID: 15172445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Corneal endothelial cells activate innate and acquired arm of anti-viral responses after cytomegalovirus infection.
    Miyazaki D; Uotani R; Inoue M; Haruki T; Shimizu Y; Yakura K; Yamagami S; Suzutani T; Hosogai M; Isomura H; Inoue Y
    Exp Eye Res; 2017 Aug; 161():143-152. PubMed ID: 28648760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood.
    Chen SF; Tu WW; Sharp MA; Tongson EC; He XS; Greenberg HB; Holmes TH; Wang Z; Kemble G; Manganello AM; Adler SP; Dekker CL; Lewis DB; Arvin AM
    J Infect Dis; 2004 May; 189(9):1619-27. PubMed ID: 15116298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation.
    Horowitz A; Guethlein LA; Nemat-Gorgani N; Norman PJ; Cooley S; Miller JS; Parham P
    J Immunol; 2015 Nov; 195(9):4524-36. PubMed ID: 26416275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
    Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S
    J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.